Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MRSN

Mersana Therapeutics Inc

May 10 • 04:00PM ET

2.71

Dollar change +0.25
Percentage change 9.94	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM VTWO IWO IWN LABU PTH IWC VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.14	Insider Own	24.18%	Shs Outstand	120.71M	Perf Week	-21.68%
Market Cap	331.60M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	-0.22%	Shs Float	92.78M	Perf Month	-27.15%
Income	-134.81M	PEG	-	EPS next Q	-0.17	Inst Own	72.75%	Short Float	11.77%	Perf Quarter	-30.15%
Sales	38.30M	P/S	8.66	EPS this Y	58.36%	Inst Trans	4.06%	Short Ratio	5.03	Perf Half Y	108.46%
Book/sh	0.23	P/B	11.85	EPS next Y	-17.95%	ROA	-54.52%	Short Interest	10.92M	Perf Year	-66.46%
Cash/sh	1.50	P/C	1.81	EPS next 5Y	-	ROE	-292.19%	52W Range	0.80 - 9.62	Perf YTD	16.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.93%	ROI	-257.73%	52W High	-71.83%	Beta	1.52
Dividend TTM	-	Quick Ratio	3.51	Sales past 5Y	12371.94%	Gross Margin	95.77%	52W Low	238.16%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	3.51	EPS Y/Y TTM	46.52%	Oper. Margin	-350.30%	RSI (14)	33.83	Volatility	13.35% 9.03%
Employees	123	Debt/Eq	1.18	Sales Y/Y TTM	18.40%	Profit Margin	-352.01%	Recom	1.44	Target Price	6.38
Option/Short	Yes / Yes	LT Debt/Eq	0.87	EPS Q/Q	69.56%	Payout	-	Rel Volume	1.29	Prev Close	2.46
Sales Surprise	8.73%	EPS Surprise	10.31%	Sales Q/Q	18.50%	Earnings	May 09 BMO	Avg Volume	2.17M	Price	2.71
SMA20	-17.77%	SMA50	-36.18%	SMA200	6.64%	Trades		Volume	2,807,107	Change	9.94%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral	$5
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform	$2 → $7
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy	$7
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy	$6
Dec-04-23	Upgrade	Citigroup	Neutral → Buy	$1 → $5
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral	$7 → $1
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral	$11 → $5
Jun-15-23	Initiated	Guggenheim	Buy	$14
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight	$10
Jan-20-23	Initiated	Citigroup	Buy	$12
Nov-21-22	Initiated	Truist	Buy	$12
Oct-15-21	Resumed	BTIG Research	Buy	$32
Aug-30-21	Initiated	H.C. Wainwright	Buy	$28
Mar-31-21	Initiated	Credit Suisse	Neutral	$18

Show Previous Ratings

May-10-24 04:36PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.94%
03:15PM	Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com)
May-09-24 11:55AM	MRSN Stock Earnings: Mersana Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -27.50%
08:05AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:59AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
04:30PM	Loading…
May-03-24 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 08:00AM	Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024 (GlobeNewswire)
Apr-04-24 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-29-24 08:41AM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.16%
Feb-28-24 09:49PM	Q4 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.58%
08:10AM	Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:35AM	Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 08:01AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.17%
Feb-21-24 08:00AM	Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024 (GlobeNewswire)
10:00AM	Loading…
Feb-20-24 10:00AM	Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-01-24 08:00AM	Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire) +6.96%
Jan-05-24 08:01AM	Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-01-23 04:30PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15%
Nov-08-23 02:42PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:13AM	Q3 2023 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:10AM	Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 04:30PM	Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023 (GlobeNewswire) +7.21%
08:00AM	Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056 (GlobeNewswire)
Sep-07-23 06:30AM	The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure (American City Business Journals)
Sep-06-23 07:00AM	Mersana Therapeutics Announces Changes in Leadership (GlobeNewswire) +7.89%
Aug-18-23 09:35AM	After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN) (Zacks)
Aug-16-23 09:35AM	Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround (Zacks) -6.35%
Aug-08-23 09:40AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Loading…
08:00AM	Mersana Therapeutics Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.24%
Jul-28-23 10:13AM	Block upgraded, Southwest downgraded: Wall Street's top analyst calls (The Fly) +17.76%
03:14AM	4 big analyst cuts: Snap slashed to Hold, Southwest gets several downgrades (Investing.com)
Jul-27-23 09:34PM	EcoR1 Capital, LLC Acquires Significant Stake in Mersana Therapeutics Inc (GuruFocus.com) -72.63%
01:44PM	Mersana slashes half its staff, loses $400M in value after trial failure (American City Business Journals)
07:06AM	Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization (GlobeNewswire)
Jul-13-23 09:45AM	15 Best Penny Stocks To Buy Now (Insider Monkey)
Jul-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)
Jun-16-23 10:43AM	Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold (Zacks) -10.80%
02:26AM	5 big analyst cuts: SoFi Technologies slashed with 3 downgrades, shares plunge (Investing.com)
Jun-15-23 09:32AM	Coinbase Is Falling, but a Nasdaq Biotech Stock Is Thursday's Big Loser (Motley Fool) -59.27%
07:36AM	US FDA puts Mersana Therapeutics's ovarian cancer study on hold (Reuters)
07:30AM	Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials (GlobeNewswire)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +5.45%
Jun-02-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-23 09:06AM	Those who invested in Mersana Therapeutics (NASDAQ:MRSN) a year ago are up 127% (Simply Wall St.)
May-24-23 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-23 08:35AM	Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.82%
07:00AM	Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.00%
May-03-23 08:00AM	Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire) +46.12%
May-02-23 08:00AM	Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023 (GlobeNewswire) -7.01%
Apr-26-23 04:05PM	Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia)
Apr-17-23 11:07AM	Getting In Cheap On Mersana Therapeutics, Inc. (NASDAQ:MRSN) Is Unlikely (Simply Wall St.) +5.54%
Apr-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-05-23 02:00PM	J.P. Morgan Suggests 2 Stocks to Buy, Including One With 140% Upside Potential (TipRanks)
Mar-16-23 11:20AM	Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More (Zacks) +6.37%
Mar-13-23 02:00PM	FDA Halts Mersana's Early-Stage Cancer Trial After Patient Death (Benzinga)
07:54AM	UPDATE 1-U.S. FDA places Mersana's cancer drug trial on hold following death (Reuters)
07:30AM	Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial (GlobeNewswire)
Mar-10-23 07:10PM	Mersana Therapeutics Provides Statement About SVB (GlobeNewswire) -12.00%
Mar-03-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-02-23 08:55PM	Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 05:24AM	Mersana Therapeutics Full Year 2022 Earnings: US$2.18 loss per share (vs US$2.41 loss in FY 2021) (Simply Wall St.)
Feb-28-23 11:51PM	Q4 2022 Mersana Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +11.60%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-21-23 08:00AM	Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023 (GlobeNewswire)
Feb-03-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-23 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-01-23 08:00AM	Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer (GlobeNewswire)
Jan-25-23 08:00AM	Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors (GlobeNewswire)
Jan-20-23 03:16PM	With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics (Benzinga) +9.97%
Jan-16-23 02:18AM	Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock? (Zacks)
Jan-06-23 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.31%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones (GlobeNewswire)
Dec-31-22 07:42AM	Estimating The Fair Value Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) (Simply Wall St.)
Dec-23-22 12:46PM	Merck KGaA inks deal worth up to $830M with Cambridge cancer biotech (American City Business Journals)
10:08AM	Mersana Inks Cancer Therapy Development Deal With Merck Germany (Benzinga)
Dec-22-22 04:08PM	Mersana signs deal with Merck KGaA for cancer therapy development (Reuters)
04:05PM	Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates (GlobeNewswire)
Dec-14-22 08:00AM	European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer (GlobeNewswire)
Dec-02-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.09%
Nov-08-22 08:00AM	Mersana Therapeutics to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-22 08:25AM	Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -11.94%
07:00AM	Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-31-22 08:00AM	Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022 (GlobeNewswire) +9.47%
Oct-30-22 10:13AM	Investing in Mersana Therapeutics (NASDAQ:MRSN) three years ago would have delivered you a 284% gain (Simply Wall St.)
Oct-17-22 09:40AM	Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year? (Zacks) +8.51%
Oct-06-22 04:05PM	Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer (GlobeNewswire)
Oct-04-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.44%
Sep-30-22 08:02AM	Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies (GlobeNewswire) +5.30%
Sep-12-22 08:00AM	Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer (GlobeNewswire)
Sep-06-22 08:00AM	Mersana Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Sep-02-22 04:05PM	Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-22 10:17AM	10 Best Biotech Stocks Under $10 (Insider Monkey)
Aug-16-22 09:55AM	Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) -6.23%

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Protopapas Anna	Director	Jan 16 '24	Sale	2.71	29,399	79,671	125,153	Jan 17 05:21 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 16 '24	Sale	2.71	10,409	28,208	199,329	Jan 17 05:19 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 16 '24	Sale	2.71	9,327	25,276	54,511	Jan 17 05:18 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 16 '24	Sale	2.71	5,025	13,618	23,328	Jan 17 05:20 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 16 '24	Sale	2.71	4,381	11,873	27,403	Jan 17 05:18 PM
Bala Mohan	SVP, Chief Development Officer	Jan 16 '24	Sale	2.71	3,431	9,298	14,052	Jan 17 05:16 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Jan 16 '24	Sale	2.71	3,357	9,097	17,966	Jan 17 05:21 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 15 '24	Option Exercise	0.00	15,208	0	209,738	Jan 17 05:19 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 15 '24	Option Exercise	0.00	10,208	0	63,838	Jan 17 05:18 PM
Protopapas Anna	Director	Jan 15 '24	Option Exercise	0.00	38,958	0	154,552	Jan 17 05:21 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 15 '24	Option Exercise	0.00	5,352	0	28,353	Jan 17 05:20 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 14 '24	Option Exercise	0.00	4,783	0	23,001	Jan 17 05:20 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Jan 14 '24	Option Exercise	0.00	1,458	0	21,323	Jan 17 05:21 PM
Protopapas Anna	Director	Jan 14 '24	Option Exercise	0.00	16,750	0	115,594	Jan 17 05:21 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 14 '24	Option Exercise	0.00	2,500	0	31,784	Jan 17 05:18 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 14 '24	Option Exercise	0.00	6,250	0	55,630	Jan 17 05:18 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 14 '24	Option Exercise	0.00	4,792	0	194,530	Jan 17 05:19 PM
Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	Jan 13 '24	Option Exercise	0.00	9,375	0	189,738	Jan 17 05:19 PM
DeSchuytner Brian	SVP, COO & CFO	Jan 13 '24	Option Exercise	0.00	10,000	0	47,380	Jan 17 05:18 PM
Carvajal Alejandra	SVP, Chief Legal Officer	Jan 13 '24	Option Exercise	0.00	8,958	0	29,284	Jan 17 05:18 PM
Bala Mohan	SVP, Chief Development Officer	Jan 13 '24	Option Exercise	0.00	8,750	0	17,483	Jan 17 05:16 PM
Protopapas Anna	Director	Jan 13 '24	Option Exercise	0.00	31,250	0	98,844	Jan 17 05:21 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Jan 13 '24	Option Exercise	0.00	7,083	0	19,865	Jan 17 05:21 PM
Mandelia Ashish	VP, Chief Accounting Officer	Jan 13 '24	Option Exercise	0.00	2,645	0	18,218	Jan 17 05:20 PM
Bala Mohan	SVP, Chief Development Officer	Oct 26 '23	Sale	1.13	1,912	2,161	8,733	Oct 27 04:07 PM
Bala Mohan	SVP, Chief Development Officer	Oct 25 '23	Option Exercise	0.00	6,250	0	10,645	Oct 27 04:07 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Aug 17 '23	Sale	1.18	1,908	2,251	11,507	Aug 18 04:01 PM
MISRA TUSHAR	SVP, Chief Manuf. Officer	Aug 16 '23	Option Exercise	0.00	6,250	0	13,415	Aug 18 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRSN

Mersana Therapeutics Inc

Upgrade your FINVIZ experience